Isofol Medical: Rights issue outcome - Redeye

Redeye comments on Isofol’s recently announced rights issue outcome. The offering was oversubscribed by 120%, raising gross proceeds of approximately SEK91m, reflecting strong shareholder support and renewed investor confidence in the company’s clinical development of arfolitixorin. We see this as an important step that strengthens Isofol’s financial position and renewed strategy.

Länk till analysen i sin helhet: https://www.redeye.se/research/1117043/isofol-medical-rights-issue-outcome